已发表论文

结直肠癌中 PD-L2 表达的临床病理分析

 

Authors Guo PD, Sun ZW, Lai HJ, Yang J, Wu PP, Guo YD, Sun J

Received 15 June 2018

Accepted for publication 15 August 2018

Published 1 November 2018 Volume 2018:11 Pages 7635—7642

DOI https://doi.org/10.2147/OTT.S177329

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 2

Editor who approved publication: Dr Sanjeev Srivastava

Background: (PD-L2), a ligand of programmed cell death protein 1 (PD-1), is an inhibitory receptor of T cells and activated B cells. Many studies have focused on PD-L1, another ligand of PD-1, and the prognostic significance of PD-L1 has been reported in many tumors. However, the expression of PD-L2 in relation to clinical outcomes has not been fully investigated in cancer patients.
Patients and methods: In this study, we investigated the expression of PD-L2 via immunohistochemistry (IHC) in the pathological specimens of 348 patients treated for colorectal cancer (CRC).
Results: Strong PD-L2 expression was found in the cancer tissues from 41% of the CRC patients who also had a high TNM stage and carcinoembryonic antigen (CEA) concentration. We also carried out functional studies in vitro, which showed that PD-L2 did not influence the growth of the CRC cell line HCT116, but increased cell invasion.
Conclusion: Collectively, these findings suggest that PD-L2 may be a potential therapeutic target for CRC.
Keywords: PD-L2, colorectal cancer, migration, therapeutic target




Figure 3 There was no effect of PD-L2 on cell growth in the CRC cell line.